Literature DB >> 20725056

Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT Trial.

Ajay K Gupta1, Neil R Poulter, Joanna Dobson, Sandra Eldridge, Francesco P Cappuccio, Mark Caulfield, David Collier, J Kennedy Cruickshank, Peter S Sever, Gene Feder.   

Abstract

BACKGROUND: Some studies suggest that blood pressure (BP)-lowering effects of commonly used antihypertensive drugs differ among ethnic groups. However, differences in the response to second-line therapy have not been studied extensively.
METHODS: In the BP-lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA), BP levels of European (n = 4,368), African (203), and South-Asian- (132) origin patients on unchanged monotherapy (atenolol or amlodipine) and/or on second-line therapy (added thiazide or perindopril) were compared. Interaction between ethnicity and BP responses (defined as end BP minus start of therapy BP) to both first- and second-line therapies were assessed in regression models after accounting for age, sex, and several other potential confounders.
RESULTS: BP response to atenolol and amlodipine monotherapy differed among the three ethnic groups (interaction test P = 0.05). Among those allocated atenolol monotherapy, black patients were significantly less responsive (mean systolic BP (SBP) difference +1.7 (95% confidence interval: -1.1 to 4.6) mm Hg) compared to white patients (referent). In contrast, BP response to amlodipine monotherapy did not differ significantly by ethnic group. BP responses to the addition of second-line therapy also differed significantly by ethnic group (interaction test P = 0.004). On adding a diuretic to atenolol, BP lowering was similar among blacks and South-Asians as compared to whites (referent). However, on addition of perindopril to amlodipine, BP responses differed significantly: compared to whites (SBP difference -1.7 (-2.8 to -0.7) mm Hg), black patients had a lesser response (SBP difference 0.8 (-2.5 to 4.2) mm Hg) and South-Asians had a greater response (SBP difference -6.2 (-10.2 to -2.2) mm Hg).
CONCLUSIONS: We found important differences in BP responses among ethnic groups to both first- and second-line antihypertensive therapies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20725056     DOI: 10.1038/ajh.2010.105

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  24 in total

1.  In vivo β-adrenergic receptor responsiveness: ethnic differences in the relationship with symptoms of depression and fatigue.

Authors:  Frank Euteneuer; Michael G Ziegler; Paul J Mills; Winfried Rief; Joel E Dimsdale
Journal:  Int J Behav Med       Date:  2014

2.  Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients.

Authors:  Elizabeth O Ofili; Dion H Zappe; Das Purkayastha; Rita Samuel; James R Sowers
Journal:  Am J Ther       Date:  2013-01       Impact factor: 2.688

Review 3.  The Advantages and Challenges of Diversity in Pharmacogenomics: Can Minority Populations Bring Us Closer to Implementation?

Authors:  Honghong Zhang; Tanima De; Yizhen Zhong; Minoli A Perera
Journal:  Clin Pharmacol Ther       Date:  2019-08       Impact factor: 6.875

4.  Comparison of bisoprolol to a metoprolol CR/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE study.

Authors:  Tianlun Yang; Yinong Jiang; Yuming Hao; Shuxian Zhou; Xinjuan Xu; Baiming Qu; Xue Lin; Tianrong Ma
Journal:  Hypertens Res       Date:  2016-08-18       Impact factor: 3.872

5.  Race and sex differences in cardiovascular α-adrenergic and β-adrenergic receptor responsiveness in men and women with high blood pressure.

Authors:  Andrew Sherwood; LaBarron K Hill; James A Blumenthal; Kristy S Johnson; Alan L Hinderliter
Journal:  J Hypertens       Date:  2017-05       Impact factor: 4.844

6.  Race/ethnicity and response to blood pressure lowering treatment after intracerebral hemorrhage.

Authors:  Mohammad Anadani; Adnan I Qureshi; Sarah Menacho; Ramesh Grandhi; Shadi Yaghi; Mouhammad A Jumaa; Adam de Havenon
Journal:  Eur Stroke J       Date:  2021-09-21

7.  A prediction model for the response to oral labetalol for the treatment of antenatal hypertension.

Authors:  D Stott; M Bolten; M Salman; D Paraschiv; A Douiri; N A Kametas
Journal:  J Hum Hypertens       Date:  2016-07-28       Impact factor: 3.012

8.  Differences in the classification of hypertensive controlled patient in primary care: Cross sectional study.

Authors:  Lena Barrera; Christopher Millett; Marta Blangiardo; Utz J Pape; Azeem Majeed
Journal:  JRSM Short Rep       Date:  2012-10-18

9.  Pharmacometabolomics reveals racial differences in response to atenolol treatment.

Authors:  William R Wikoff; Reginald F Frye; Hongjie Zhu; Yan Gong; Stephen Boyle; Erik Churchill; Rhonda M Cooper-Dehoff; Amber L Beitelshees; Arlene B Chapman; Oliver Fiehn; Julie A Johnson; Rima Kaddurah-Daouk
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

10.  Excellent tolerance to cilnidipine in hypertensives with amlodipine - induced edema.

Authors:  Ranjan Shetty; G Vivek; Kushal Naha; Anil Tumkur; Abhinav Raj; K L Bairy
Journal:  N Am J Med Sci       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.